IL-17 inhibitor therapy and risk of chronic obstructive pulmonary disease and related pulmonary outcomes in patients with psoriasis: A real-world cohort study.
文献摘要
Background The interleukin-17 (IL-17)/T helper 17 axis has been implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, although pulmonary safety concerns have limited enthusiasm for IL-17-targeted therapies. We evaluated pulmonary outcomes associated with IL-17 inhibitors in patients with psoriasis. Methods We performed a retrospective cohort study using the TriNetX Research Network. Adults with psoriasis were identified and categorized into IL-17 inhibitor exposure cohorts (secukinumab, ixekizumab, brodalumab, or bimekizumab) or matched psoriasis controls without IL-17 exposure. A target trial emulation framework with 1:1 propensity score matching adjusted for demographics, comorbidities, nicotine dependence, and healthcare utilization. Outcomes included incident COPD, COPD exacerbation or lower respiratory infection, respiratory infections, respiratory failure, persistent asthma, oxygen dependence, pulmonary hypertension, hypoxemia, and interstitial lung disease. Results After matching, 28,706 IL-17-treated patients and 28,706 controls were analyzed. IL-17 inhibition was associated with lower risks of COPD (2.5% vs 3.6%; hazard ratio [HR], 0.74; 95% CI, 0.67-0.81), respiratory infections (HR, 0.68; 95% CI, 0.64-0.71), respiratory failure (HR, 0.84; 95% CI, 0.76-0.93), persistent asthma (HR, 0.80; 95% CI, 0.70-0.91), oxygen dependence (HR, 0.77; 95% CI, 0.66-0.90), pulmonary hypertension (HR, 0.79; 95% CI, 0.68-0.90), and hypoxemia (HR, 0.87; 95% CI, 0.78-0.96) (all p ≤ 0.008). Ixekizumab demonstrated the largest risk reductions. No increased signal for interstitial lung disease was observed. Conclusions In this large real-world cohort, IL-17 inhibitor therapy in psoriasis was associated with reduced incidence of multiple pulmonary outcomes, supporting the need for future prospective research into the effects of IL-17 inhibitor therapy on pulmonary morbidity.